Medicamen Biotech Limited Stock

Equities

MEDICAMEQ

INE646B01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-04-29 EDT 5-day change 1st Jan Change
589.6 INR +20.00% Intraday chart for Medicamen Biotech Limited +40.96% -2.14%

Financials

Sales 2022 1.15B 13.84M 18.91M Sales 2023 1.41B 16.88M 23.07M Capitalization 8.29B 99.41M 136M
Net income 2022 149M 1.79M 2.44M Net income 2023 148M 1.77M 2.42M EV / Sales 2022 7 x
Net Debt 2022 220M 2.63M 3.6M Net Debt 2023 49.3M 591K 807K EV / Sales 2023 5.92 x
P/E ratio 2022
52.8 x
P/E ratio 2023
55 x
Employees 388
Yield 2022
0.16%
Yield 2023
0.15%
Free-Float 40.22%
More Fundamentals * Assessed data
Dynamic Chart
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Medicamen Biotech Limited Recommends Final Dividend for Financial Year 2022-23 CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
INDIA STOCKS-Indian shares seen opening higher as global equities attempt bounce RE
Medicamen Biotech Forays into Domestic Indian Pharmaceutical Business MT
Medicamen Biotech Forms New Unit MT
Medicamen Biotech Ties Up with Danish Pharmaceutical Firm for Manufacturing of Drugs MT
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22 CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
More news
1 day+20.00%
1 week+40.96%
Current month+53.89%
1 month+53.89%
3 months+10.52%
6 months-3.62%
Current year-2.14%
More quotes
1 week
417.50
Extreme 417.5
589.55
1 month
390.50
Extreme 390.5
589.55
Current year
356.75
Extreme 356.75
604.00
1 year
356.75
Extreme 356.75
903.50
3 years
356.75
Extreme 356.75
1 219.00
5 years
153.10
Extreme 153.1
1 219.00
10 years
7.60
Extreme 7.6
1 219.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 18-07-24
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 59 93-12-21
Chief Executive Officer - -
Director/Board Member 62 19-02-10
More insiders
Date Price Change Volume
24-04-29 589.6 +20.00% 67,580
24-04-26 491.3 +17.07% 12,595
24-04-25 419.6 -3.33% 2,353
24-04-24 434.1 +0.22% 856
24-04-23 433.2 +3.56% 5,612

Delayed Quote Bombay S.E., April 29, 2024 at 06:00 am

More quotes
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.
More about the company
  1. Stock Market
  2. Equities
  3. MEDICAMEQ Stock